BioArctic AB (publ) (BIOABS.XC)
| Previous close | 279.80 |
| Open | 288.40 |
| Bid | 235.40 x 0 |
| Ask | 239.80 x 0 |
| Day's range | 279.80 - 279.80 |
| 52-week range | 275.80 - 332.10 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 23.841B |
| Beta (5Y monthly) | -0.15 |
| PE ratio (TTM) | 96.15 |
| EPS (TTM) | 2.91 |
| Earnings date | 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 10 May 2019 |
| 1y target est | N/A |
Simply Wall St.3 Swedish Exchange Growth Companies With High Insider Ownership And Earnings Growth Of At Least 33%
As global markets experience varied trends with Europe showing signs of recovery and Asia displaying mixed signals, Sweden's market remains a focal point for growth-oriented investors. In such an environment, companies with high insider ownership can signal strong confidence in future prospects, making them particularly compelling in the context of Sweden's robust economic framework.
PR NewswireFDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for less frequent monthly lecanemab-irmb (U.S. brand name: Leqembi) intravenous (IV) maintenance dosing. A Prescription Drug User Fee Act (PDUFA) action date is set for January 25, 2025. In the US, Leqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive
Simply Wall St.Swedish Exchange Growth Leaders With High Insider Stakes
As global markets navigate through a landscape marked by fluctuating inflation rates and cautious monetary policies, Sweden's stock market presents a unique blend of opportunities, particularly in growth companies with high insider ownership. These firms often benefit from aligned interests between shareholders and management, potentially leading to more resilient performance in uncertain economic times.
